Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis in Critical Care
2022
AOU Città della Salute di Torino
Tipo pubblicazione
Article
Autori/Collaboratori (717)Vedi tutti...
Potzner K
Medical College of Wisconsin (Froedtert Hospital), Milwaukee, United States
Zimmermann C
Medical College of Wisconsin (Froedtert Hospital), Milwaukee, United States
Guy J
Medical College of Wisconsin (Froedtert Hospital), Milwaukee, United States
et alii...
Abstract
Background: The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients with moderate-to-severe ARDS the impact of early use of NMBAs on 90-day mortality, through propensity score (PS) matching analysis. Methods: We analyzed a convenience sample of patients with COVID-19 and moderate-to-severe ARDS, admitted to 244 intensive care units within the COVID-19 Critical Care Consortium, from February 1, 2020, through October 31, 2021. Patients undergoing at least 2 days and up to 3 consecutive days of NMBAs (NMBA treatment), within 48 h from commencement of IMV were compared with subjects who did not receive NMBAs or only upon commencement of IMV (control). The primary objective in the PS-matched cohort was comparison between groups in 90-day in-hospital mortality, assessed through Cox proportional hazard modeling. Secondary objectives were comparisons in the numbers of ventilator-free days (VFD) between day 1 and day 28 and between day 1 and 90 through competing risk regression. Results: Data from 1953 patients were included. After propensity score matching, 210 cases from each group were well matched. In the PS-matched cohort, mean (± SD) age was 60.3 ± 13.2 years and 296 (70.5%) were male and the most common comorbidities were hypertension (56.9%), obesity (41.1%), and diabetes (30.0%). The unadjusted hazard ratio (HR) for death at 90 days in the NMBA treatment vs control group was 1.12 (95% CI 0.79, 1.59, p = 0.534). After adjustment for smoking habit and critical therapeutic covariates, the HR was 1.07 (95% CI 0.72, 1.61, p = 0.729). At 28 days, VFD were 16 (IQR 0–25) and 25 (IQR 7–26) in the NMBA treatment and control groups, respectively (sub-hazard ratio 0.82, 95% CI 0.67, 1.00, p = 0.055). At 90 days, VFD were 77 (IQR 0–87) and 87 (IQR 0–88) (sub-hazard ratio 0.86 (95% CI 0.69, 1.07; p = 0.1
Se sei accreditato in BVS-P effettua l'accesso per utilizzare i nostri servizi.
PMID : 35581612
DOI : 10.1186/s13054-022-03983-5
Keywords
very elderly; treatment duration; time to treatment; smoking habit; short course therapy; regression analysis; proportional hazards model; propensity score; diabetes mellitus; disease severity; female; gender; hazard ratio; hospital admission; human; hypertension; in-hospital mortality; intensive care; intensive care unit; invasive ventilation; major clinical study; male; middle aged; morbidity; obesity; coronavirus disease 2019; neuromuscular blocking agent; adult; adult respiratory distress syndrome; aged; article; cohort analysis; comorbidity; confidence interval; controlled study;